Sensus Healthcare, Inc. (SRTS) Stock Price & Analysis
Sensus Healthcare, Inc. (SRTS) closed at USD 2.77 on Thursday, October 15, 2026, down 3.15% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.86; the Oct 15, 2026 session ranged USD 2.71–2.87 on volume of 25,962 shares. Market capitalization is $45.60M, with a 52-week range of USD 2.66–5.49 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SRTS.md
Key facts (SRTS)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 5.38 (range 4–6).
- Total return with dividends: 1Y -16.3% vs S&P 500 +18.1%; 5Y -30.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.04, revenue estimate $6.6M.
Analysts (SRTS)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 5.38 (low 4, high 6).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Lake Street | Target lowered | Buy | $4.5 → $4 |
Total return (dividends reinvested) (SRTS)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -16.3% | -30.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -16.4% | -7.0% |
| Volatility (annualized) | 65.2% | 82.5% |
| Max drawdown | -49.3% (Jan 2026→Jun 2026) | -87.3% (Aug 2022→Nov 2023) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 2.77 |
|---|---|
| Change | ▼ 3.15% (down) |
| Previous Close | USD 2.86 |
| Open | USD 2.85 |
| Day Range | USD 2.71 – 2.87 |
| 52-Week Range | USD 2.66 – 5.49 |
| Volume | 25,962 shares |
| Market Cap | $45.60M |
| Exchange | NCM |
Technical Analysis (SRTS)
Nexqual's technical model rates SRTS "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.53 (oversold) |
| vs SMA50 | Below (USD 3.09) |
| MACD | -0.07 (negative) |
Analyst Ratings (SRTS)
Wall Street analysts rate SRTS "Buy" based on 4 analysts, with a mean price target of USD 5.38 (range USD 4–6), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 5.38 |
| High Target | USD 6 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SRTS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.04 |
| Revenue Estimate | $6.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.53 vs est -0.11 ▼ miss |
| 2026-03-31 | USD -0.16 vs est -0.11 ▼ miss |
| 2025-12-31 | USD -0.19 vs est -0.06 ▼ miss |
| 2025-09-30 | USD -0.06 vs est -0.11 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (SRTS)
| Total Revenue | $17.51M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -68.70% |
| Gross Margin | +36.39% |
| Operating Margin | -138.87% |
| Profit Margin | -88.45% |
| ROE | -34.83% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.71 |
| Total Cash | $15.19M |
| Total Debt | $343,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (SRTS)
Nexqual rates Sensus Healthcare, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -34% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $15M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Critical — ROE -35%, ROA -16.5% |
Ownership (SRTS)
| Insider Ownership | +18.67% |
|---|---|
| Institutional Ownership | +27.51% |
| Shares Outstanding | 16.46M |
| Float | 13.39M |
| Short % of Float | +1.54% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (SRTS)
Sensus Healthcare, Inc. is led by Joseph C. Sardano (age 72), Co-Founder, Chairman & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Co-Founder, Chairman & CEO | Joseph C. Sardano (age 72) |
|---|---|
| President, Chief Commercial Officer, General Counsel, Corporate Secretary & Director | Michael J. Sardano (age 37) |
| Chief Financial Officer | Javier Rampolla (age 52) |
| Chief Operating Officer | Magdalena Martinez (age 35) |
| Chief Technology Officer | Carlton Chow (age 35) |
Major Backers & Investors (SRTS)
Notable institutional backers of Sensus Healthcare, Inc. include Pacific Ridge Capital Partners, LLC, RBB Fund, Inc.-Adara Smaller Companies Fund, Divisadero Street Capital Management, LP, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pacific Ridge Capital Partners, LLC | 4.8% |
| RBB Fund, Inc.-Adara Smaller Companies Fund | 1.89% |
| Divisadero Street Capital Management, LP | 1.69% |
| Renaissance Technologies | 1.47% |
| UBS Group AG | 0.93% |
| Sachetta, LLC | 0.92% |
| 360 Funds-M3Sixty Income and Opportunity Fund | 0.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.95% |
| Dimensional Fund Advisors | 2.1% |
| Geode Capital | 0.94% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt